Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...
Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of ...
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...
Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
A new vaccine is changing how doctors treat certain skin cancer patients, according to doctors in the ArkLaTex.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...
Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
12h
Breast cancer: Auckland woman who spent $120,000 on Keytruda says response to petition ‘disgraceful’
An Auckland woman who has spent months campaigning for cancer drug funding says the Petitions Select Committee’s response to ...
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results